Propylene glycol inactivates respiratory viruses and prevents airborne transmission
© 2023 The Authors. Published under the terms of the CC BY 4.0 license..
Viruses are vulnerable as they transmit between hosts, and we aimed to exploit this critical window. We found that the ubiquitous, safe, inexpensive and biodegradable small molecule propylene glycol (PG) has robust virucidal activity. Propylene glycol rapidly inactivates a broad range of viruses including influenza A, SARS-CoV-2 and rotavirus and reduces disease burden in mice when administered intranasally at concentrations commonly found in nasal sprays. Most critically, vaporised PG efficiently abolishes influenza A virus and SARS-CoV-2 infectivity within airborne droplets, potently preventing infection at levels well below those tolerated by mammals. We present PG vapour as a first-in-class non-toxic airborne virucide that can prevent transmission of existing and emergent viral pathogens, with clear and immediate implications for public health.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
EMBO molecular medicine - 15(2023), 12 vom: 07. Dez., Seite e17932 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Styles, Christine T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Airborne transmission |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.15252/emmm.202317932 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364622075 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364622075 | ||
| 003 | DE-627 | ||
| 005 | 20240320233645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15252/emmm.202317932 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM364622075 | ||
| 035 | |a (NLM)37970627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Styles, Christine T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Propylene glycol inactivates respiratory viruses and prevents airborne transmission |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Published under the terms of the CC BY 4.0 license. | ||
| 520 | |a Viruses are vulnerable as they transmit between hosts, and we aimed to exploit this critical window. We found that the ubiquitous, safe, inexpensive and biodegradable small molecule propylene glycol (PG) has robust virucidal activity. Propylene glycol rapidly inactivates a broad range of viruses including influenza A, SARS-CoV-2 and rotavirus and reduces disease burden in mice when administered intranasally at concentrations commonly found in nasal sprays. Most critically, vaporised PG efficiently abolishes influenza A virus and SARS-CoV-2 infectivity within airborne droplets, potently preventing infection at levels well below those tolerated by mammals. We present PG vapour as a first-in-class non-toxic airborne virucide that can prevent transmission of existing and emergent viral pathogens, with clear and immediate implications for public health | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a airborne transmission | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a propylene glycol | |
| 650 | 4 | |a virucide | |
| 650 | 7 | |a Propylene Glycols |2 NLM | |
| 700 | 1 | |a Zhou, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Flight, Katie E |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Jonathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Vanden Oever, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Peacock, Thomas P |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ziyin |e verfasserin |4 aut | |
| 700 | 1 | |a Millns, Rosie |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neill, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Borodavka, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Grove, Joe |e verfasserin |4 aut | |
| 700 | 1 | |a Barclay, Wendy S |e verfasserin |4 aut | |
| 700 | 1 | |a Tregoning, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Edgar, Rachel S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EMBO molecular medicine |d 2009 |g 15(2023), 12 vom: 07. Dez., Seite e17932 |w (DE-627)NLM192618962 |x 1757-4684 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:12 |g day:07 |g month:12 |g pages:e17932 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15252/emmm.202317932 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 12 |b 07 |c 12 |h e17932 | ||